海外の治験の状況「前立腺癌」での検索結果
241件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy.
- Castration-resistant prostate cancer (patients who have achieved response to first-line docetaxel chemotherapy). MedDRA version: 16.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-04-09
Authorised
- uPAR-PET/MRI in patients with prostate cancer for evaluation of tumor aggressiveness
- Prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Denmark
- 2017-06-28
Authorised
- A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer
- Hormone refractory prostate cancer
- United Kingdom
- 2005-06-21
Authorised
- A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC) - Melphalan in AIPC / Mel-CaP
- Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.)
- United Kingdom
- 2006-09-18
Authorised
- A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer - Metformin use in patients on ADT to prevent Metabolic Syndrome
- Patients with prostate cancer on androgen deprivation therapy (ADT). Randomisation between standard treatment with ADT only, and the additional use of metformin with dietary and exercise advice. Aim is to reduce the prevalence of metabolic syndrome in the intervention arm - this is a condition linked to ADT in prostate cancer patients MedDRA version: 9.1 Level: LLT Classification code 10001186 Term: Adenocarcinoma of prostate MedDRA version: 9.1 Level: LLT Classification code 10052066 Term: Metabolic syndrome
- United Kingdom
- 2007-08-01
Authorised
- EFFICACY EVALUATION OF TADALAFIL 20 MG ON DEMAND VS TADALAFIL 5 MG DAILY AS TREATMENT MODALITY FOR ERECTILE DYSFUNCTION FOLLOWING RADICAL RADIOTHERAPY IN PROSTATIC CANCER - ND
- Erectile dysfunction following radiotherapy for prostatic cancer br>MedDRA version: 6.1 Level: PT Classification code 10060862
- Italy
- 2007-06-28
Authorised
- A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- United Kingdom
- 2007-05-30
Authorised
- Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer
- Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer referring to histopathological, postoperative results
- Germany
- 2006-09-06
Authorised
- A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER - n/a
- Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC) MedDRA version: 13.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Germany, Netherlands, Spain, United Kingdom
- 2006-07-23
Authorised
- A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER - RTOG 0815
- intermediate risk prostate cancer br>MedDRA version: 12.1 Level: LLT Classification code 10026389 Term: Malignant neoplasm of prostate
- Ireland
- 2010-09-13